DANCANN PHARMA A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0252 DKK | +2.44% |
|
-3.08% | -16.00% |
| Mar. 29 | Dancann Pharma Plans Up to DKK19 Million Rights Issue | MT |
| Feb. 28 | DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge | MT |
| Sales 2021 | 874K 125K | Sales 2022 | 7.19M 1.03M | Capitalization | 37.06M 5.29M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -1.57M | Net income 2022 | -16M -2.28M | EV / Sales 2021 | 192 x |
| Net cash position 2021 | 7.74M 1.1M | Net cash position 2022 | 10.75M 1.53M | EV / Sales 2022 | 3.66 x |
| P/E ratio 2021 |
-12.7
x | P/E ratio 2022 |
-2.31
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 14.49% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.44% | ||
| 1 week | -3.08% | ||
| Current month | -66.93% | ||
| 1 month | -70.32% | ||
| 3 months | +32.63% | ||
| 6 months | -62.94% | ||
| Current year | -16.00% |
1 week
0.02
0.04
1 month
0.020.09
Current year
0.010.10
1 year
0.010.59
3 years
0.017.06
5 years
0.017.06
10 years
0.017.06
| Managers | Title | Age | Since |
|---|---|---|---|
Jeppe Rasmussen
FOU | Founder | 29 | 18-03-19 |
| Director of Finance/CFO | 52 | 23-01-03 | |
| Chief Operating Officer | 37 | 22-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carsten Trads
CHM | Chairman | 69 | - |
Tue Østergaard
BRD | Director/Board Member | 47 | 22-04-26 |
Jeppe Rasmussen
FOU | Founder | 29 | 18-03-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.0252 | +2.44% | 979,312 |
| 24-04-17 | 0.0246 | +0.82% | 334,523 |
| 24-04-16 | 0.0244 | -5.43% | 1,545,690 |
| 24-04-15 | 0.0258 | -7.86% | 3,048,934 |
| 24-04-12 | 0.028 | +7.69% | 1,319,461 |
End-of-day quote NORDIC GROWTH MARKET, April 17, 2024
More quotes
Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.00% | 600K | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.16% | 21.66B | |
| -18.35% | 20.77B | |
| -8.61% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- DANCAN Stock
